van Deventer, Leland
Bronstone, Amy
Leonardi, Claudia
Bennett, Matthew
Yager, Peter
Dasa, Vinod https://orcid.org/0000-0001-5282-4026
Article History
Received: 23 November 2022
Accepted: 4 February 2023
First Online: 20 February 2023
Declarations
:
: This study was conducted using retrospective de-identified patient data obtained for clinical purposes. The research team consulted extensively with the LSUHSC-NO Institutional Review Board (IRB). This study was approved (Protocol #1561) under the category of “exempt research” and the requirement to obtain informed consent was waived given the nature of the study and data. More information about the institution’s IRB can be accessed online ().
: Dr. Dasa is a paid speaker for Bioventus, Swiftpath, and Pacira; consultant for Bioventus and Pacira; owns stock or stock options in SIGHT Medical, My Medical Images, CyMedica Orthopedics, GrandCare Health Service, MEND Technology, and Goldfinch Health; and has received research support from SKK, Cartiheal, NIH, and OREF. The other authors have no competing interests to disclose.